ReShape Lifesciences announces $2.7 million registered direct offering
ReShape Lifesciences announced t has entered into definitive agreements with several institutional investors for the purchase of 1,241,382 shares of its common stock, at a purchase price per share of $2.05, for gross proceeds of $2.55 million, in a registered direct offering priced at-the-market. July 11, 2018